PET for Sarcomas Other Than Gastrointestinal Stromal Tumors
|
|
- Douglas Paul
- 5 years ago
- Views:
Transcription
1 PET for Sarcomas Other Than Gastrointestinal Stromal Tumors Guy C. Toner, a,c Rodney J. Hicks b,c a Division of Haematology and Medical Oncology and b Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia; c Department of Medicine, St Vincent s Medical School, University of Melbourne, Melbourne, Australia Key Words. Sarcoma PET scanning Response assessment Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article. Abstract Positron emission tomography (PET) is increasingly used to diagnose, grade, and stage different types of tumors and to assess tumor response to therapy. Metabolic data acquired by fluorine--fluorodeoxyglucose ( FDG)-PET may facilitate accurate grading of sarcomas and have prognostic value when combined with other grading methods and various clinical/radiological features. In addition, FDG-PET is currently being evaluated in several cancer types for its utility in biopsy guidance. Whole-body FDG-PET also appears to be superior to other imaging modalities in detecting bone Introduction Positron emission tomography (PET) has wide-ranging utility in sarcoma, including staging, assessment of prognosis, monitoring response, and potentially to customize treatment regimens [1 4]. Fluorine--fluorodeoxyglucose ( FDG)-PET is well suited to detecting the inherent heterogeneity of these tumors. The utility of PET in tumor grading, biopsy guidance, staging and restaging, and response evaluation and monitoring in sarcoma patients is discussed. Utility of PET for Tumor Grading An association between FDG uptake and sarcoma tumor grade was first noted in 1988 [5]. FDG-PET avidity has been shown to increase with tumor grade in both bone and soft tissue sarcomas: the glycolytic metabolic activity of high-grade tumors is higher than that of low-grade or benign metastases in certain sarcoma patients. New PET tracers currently being investigated include F-fluorothymidine ( F-FLT) and F-misonidazole. F-FLT can help to determine tumor growth, rather than tumor shrinkage, which could be used to evaluate treatment response in sarcomas. PET imaging offers invaluable information to help maximize the clinical benefit of patients with sarcoma. This article reviews the use of PET in sarcoma management and its potential applications in the near future. The Oncologist 2008;13(suppl 2):22 26 tumors [6]. In addition to histopathological grade, FDG- PET standardized uptake value (SUV) was also demonstrated to be associated with cellularity, mitotic activity, MIB labeling index, and p53 overexpression in various bone and soft tissue sarcomas [6]. Thus, metabolic data acquired by FDG-PET may facilitate accurate grading and have prognostic value in the sarcoma setting. To a certain extent, FDG-PET may be used to differentiate benign from malignant sarcomas. Significant differences in the differential uptake ratio, a quantitative index of glucose metabolism, in benign masses and malignant sarcomas have been noted by several researchers [7, 8]. However, the definition of malignant has been problematic, as has the type of sarcoma being evaluated. Furthermore, different groups have obtained conflicting results using the metabolic rate of FDG (MRFDG) as a parameter to distinguish between benign and malignant sarcomas [9 11]. Downloaded from by guest on August 14, 20 Correspondence: Guy Toner, M.D., Peter MacCallum Cancer Institute, Medical Oncology, St. Andrews Place, East Melbourne, Australia Telephone: ; Fax: ; guy.toner@petermac.org Received August 20, 2007; accepted for publication December 11, AlphaMed Press /2008/$30.00/0 doi: /theoncologist.13-S2-22 The Oncologist 2008;13(suppl 2):
2 Toner, Hicks Figure 1. CT, FDG-PET, and fused FDG-PET/CT images of a patient with a large left thigh mass consistent with liposarcoma. FDG-PET was used during biopsy to target the region with highest metabolic activity. Abbreviations: FDG-PET, fluorine--fluorodeoxyglucose positron emission tomography; CT, computed tomography. Utility of PET for Biopsy Guidance Both PET and computed tomography (CT) are very useful for biopsy guidance. As an example, Figure 1 demonstrates combined PET/CT findings in a case with a large left thigh mass with features consistent with liposarcoma. FDGPET was used during biopsy to guide the treating physician to the highest metabolic region, which allowed confirmation that this was a high-grade tumor. In this patient, multiple s.c. metastases were also detected by PET. Thus, by guiding biopsy toward the most biologically significant regions of large masses, FDG-PET can reveal information about a lesion that cannot be obtained through other imaging modalities. The use of FDG-PET in biopsy is currently being investigated in several cancer types, and may prove invaluable in several settings, including sarcomas. Utility of PET for Staging and Restaging Two independent studies reported that the sensitivity and specificity of FDG-PET for the detection of pulmonary metastases from various types of sarcoma were 50% 86.7% and 98% 100%, respectively, while the sensitivity and specificity of spiral CT of the chest were 75% 100% and 96.4% 100%, respectively [14, 15]. However, FDGPET has a higher sensitivity than CT for soft tissue metastases, and it can also be used to identify false-positive CT masses. The two groups of researchers agreed that CT and FDG-PET are both needed to accurately define the extent of disease during initial staging as well as during follow-up. Our own experience with combined PET/CT scanning over the past 3 years suggests that CT scanning is particularly helpful in localizing small lung metastases wherein partial volume effects lead to insufficient signal on PET to allow a confident diagnosis of malignancy. Conversely, for larger nodules, the presence of high uptake at other sites of disease but not in the lung nodule makes a metastatic basis very unlikely. In contrast, whole-body FDG-PET appears to be superior to other imaging modalities for detection of bone metastases in certain sarcoma patients. Compared with bone scintigraphy, FDG-PET was associated with a higher sensitivity (100% versus 68%), specificity (96% versus 87%), and accuracy (97% versus 82%) in 38 patients with histologically proven malignant primary Ewing s sarcoma [16]. Interestingly, although FDG-PET also appeared to have some value in the detection of osseous masses from osteosarcomas, it appeared to be less sensitive than bone scintigraphy in these patients. FDG-PET is also very helpful in assessing possible local recurrence and performing restaging. Detection of local recurrence is often difficult because of disturbance of the normal anatomy by previous surgery and any subse- Downloaded from by guest on August 14, 20 MRFDG does not appear to be useful for grading certain bone tumors, such as giant cell tumors, which typically show a relatively high SUV. In contrast, this methodology has been successfully used to distinguish among grade I, II, and III soft tissue sarcomas [10]. While FDG-PET alone may not be sufficient for grading sarcomas, it does have the potential to provide complementary information when coupled with other grading modalities and with various clinical/radiological features. Evaluation of FDG uptake may also have potential prognostic value. In patients with gastrointestinal stromal tumors, reductions in the FDG-PET maximum SUV have been shown to correlate with longer time to progression [12]. In a study of 74 adult patients with soft tissue sarcoma who underwent preoperative FDG-PET imaging, SUV was found to be somewhat predictive of recurrencefree survival [13]. Patients with SUVs <1.59, 1.59 to <3.6, and 3.6 had 5-year recurrence-free survival rates of 66%, 24%, and 11%, respectively. While these results are promising, further studies are required to determine whether PET information can be used as an independent prognostic variable in this patient population. 23
3 24 quent radiotherapy. Unlike some other imaging modalities, FDG-PET is not disabled by the metal susceptibility or metal beam hardening artifacts that may result from previous treatments. Several studies have indicated the high accuracy of FDG-PET for detecting late local recurrence in sarcoma patients [17 21]. Utility of PET in Response Evaluation and Monitoring Figure 2. FDG-PET and merged FDG-PET/CT images of a patient with an osteosarcoma of the left femur that was treated with neoadjuvant chemotherapy. The scans demonstrate a dramatic reduction in metabolic activity in the tumor after chemotherapy. Abbreviations: FDG-PET, fluorine--fluorodeoxyglucose positron emission tomography; CT, computed tomography. The predictive value of PET scanning has been investigated for evaluating histological response following neoadjuvant chemotherapy in patients with osteosarcoma [24 26]. The case presented in Figure 2 shows that residual metabolic activity following neoadjuvant chemotherapeutic treatment of a leg osteosarcoma can be visualized using FDG-PET. In a prospective study that evaluated the utility of FDG-PET in assessing response to neoadjuvant chemotherapy in patients with osteosarcoma, Schulte and colleagues demonstrated a strong correlation between a reduction in tumor glucose metabolism following therapy and the histologic grade of tumor regression [24]. In 25 of 27 patients, pre- and post-treatment tumor-to-background ratios (TBRs) of FDG uptake could be used to discriminate responders from nonresponders. Thus, FDG-PET provides a promising tool for noninvasive evaluation of neoadjuvant chemotherapy response in osteosarcoma. Ideally, PET scanning will be used in the near future to detect differential responses to different neoadjuvant chemotherapeutic compounds, which might facilitate patient-specific tailoring of neoadjuvant treatment and postoperative therapy. However, this type of information must be obtained through the cooperation of several research groups through well-designed clinical trials. In contrast to the current use of PET immediately before and after completion of treatment only, there is potential value in performing PET scans several times throughout treatment, as illustrated in Figure 3. This approach might allow individual assessment of response to Figure 3. Proposed clinical trial model for evaluating the utility of FDG-PET in predicting response in osteosarcoma. (A): Use of FDG-PET during a neoadjuvant sarcoma treatment regimen would allow correlation of PET response with histologic response. (B): Proposed use of FDG-PET during neoadjuvant sarcoma treatment regimen. More frequent use of FDG-PET might allow assessment of response to individual components of the treatment regimen. Abbreviations: FDG-PET, fluorine--fluorodeoxyglucose positron emission tomography; CDDP/ADM, cisplatin and doxorubicin; MTX, methotrexate. OTncologist he Downloaded from by guest on August 14, 20 The utility of FDG-PET in monitoring response has been recently demonstrated to be superior to that of CT for predicting outcome in patients with non-small cell lung cancer (NSCLC) [22]. CT and other structural imaging modalities have substantial limitations in the lung and pleura, such as irregular tumor shapes that are difficult to measure, poor contrast at the interface between tumor and normal tissue, and obstruction by radiation pneumonitis [22, 23]. In a direct head-to-head comparison, the utility of FDGPET and CT in assessing response and thereby survival in patients with NSCLC who received either radical radiotherapy or chemotherapy was evaluated. The study authors concluded that a single, early, post-treatment PET scan could significantly (p <.0001) predict survival, while CT results failed to do so [22]. FDG-PET may have similar response evaluation potential in other cancers, including sarcomas. PET for Other Sarcomas
4 Toner, Hicks 25 the different chemotherapy components of treatment. As a result, information obtained through PET scanning during therapy might potentially change a patient s treatment, ultimately affecting his or her chances of remission and survival. Future Directions: New PET Tracers While FDG PET can be used along with CT to reveal the location and malignant potential of abnormal tissue masses, PET imaging has the potential to yield additional information about tumors that could further improve diagnosis and individually tailor cancer treatment. Several alternative PET radiopharmaceuticals are currently being investigated, both preclinically and in early clinical trials, which have the potential to reveal the growth rate, oxygen use, drug resistance properties, and blood supply of tumors. Examples of new PET tracers being investigated for use in sarcoma as well as other cancers include F-fluorothymidine ( F- FLT) and F-misonidazole ( F-MISO). F-FLT is an analogue of the nucleotide thymidine, and is therefore used as a marker of DNA synthesis. When used before treatment and soon after treatment begins, F-FLT may help determine the extent to which a tumor s growth is being slowed in response to therapy. This is particularly relevant for sarcoma, in which the use of newer cytostatic agents leads to a References 1 Hicks RJ, Toner GC, Choong PF. Clinical applications of molecular imaging in sarcoma evaluation. Cancer Imaging 2005;5: Eary JF, O Sullivan F, Powitan Y et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: A retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29: Feldman F, van Heertum R, Manos C. FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 2003;32: Schulte M, Brecht-Krauss D, Heymer B et al. Grading of tumors and tumorlike lesions of bone: Evaluation by FDG PET. J Nucl Med 2000;41: Kern KA, Brunetti A, Norton JA et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988;29: Folpe AL, Lyles RH, Sprouse JT et al. (F-) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6: Adler LP, Blair HF, Makley JT et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991;32: Griffeth LK, Dehdashti F, McGuire AH et al. PET evaluation of softtissue masses with fluorine- fluoro-2-deoxy-d-glucose. Radiology 1992;2: Nieweg OE, Pruim J, van Ginkel RJ et al. Fluorine--fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37: Eary JF, Conrad EU, Bruckner JD et al. Quantitative [F-]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998;4: slower rate of tumor growth rather than tumor shrinkage. F-FLT-PET may allow changes in cell proliferation to be observed much earlier and to a much greater extent than FDG-PET. F-MISO is a marker of tumor hypoxia, which can lead to cellular responses that can potentially raise a tumor s resistance to therapy. Recent results have shown that F-MISO-PET may be useful for predicting survival in patients with head and neck cancer [27]. Conclusions In sarcoma, PET scans provide useful complementary information that must be interpreted in the overall context of the patient s imaging and other evaluations. PET can be used for grading of disease and differentiating between benign and malignant disease, biopsy evaluation, staging and restaging, assessing local recurrence, and therapeutic monitoring. However, further studies are required to improve quantitation of response, because SUVs and TBRs are at best semiquantitative, and comparison among different sites and use in clinical trials will require additional study. Finally, the potential advantages of identifying new radiopharmaceuticals such as FLT and F-MISO suggest that PET scanning will play an even larger role in the diagnosis and treatment of sarcomas in the future. 11 Kole AC, Nieweg OE, Hoekstra HJ et al. Fluorine--fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998;39: Holdsworth CH, Manola J, Badawi RD et al. Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST). J Clin Oncol 2004;22(suppl 14):197s. 13 Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A et al. Prognostic significance of preoperative [-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 2005;241: Lucas JD, O Doherty MJ, Wong JC et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br 1998;80: Franzius C, Daldrup-Link HE, Sciuk J et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: Comparison with spiral CT. Ann Oncol 2001;12: Franzius C, Sciuk J, Daldrup-Link HE et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: Comparison with bone scintigraphy. Eur J Nucl Med 2000;27: Franzius C, Daldrup-Link HE, Wagner-Bohn A et al. FDG-PET for detection of recurrences from malignant primary bone tumors: Comparison with conventional imaging. Ann Oncol 2002;13: Garcia R, Kim EE, Wong FC et al. Comparison of fluorine--fdg PET and technetium-99m-mibi SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996;37: Downloaded from by guest on August 14, 20
5 26 PET for Other Sarcomas 19 el-zeftawy H, Heiba SI, Jana S et al. Role of repeated F- fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma. Cancer Biother Radiopharm 2001;16: Bredella MA, Caputo GR, Steinbach LS. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentgenol 2002;179: Johnson GR, Zhuang H, Khan J et al. Roles of positron emission tomography with fluorine--deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin Nucl Med 2003;28: MacManus MP, Hicks RJ, Matthews JP et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21: Werner-Wasik M, Xiao Y, Pequignot E et al. Assessment of lung cancer response after nonoperative therapy: Tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 2001; Schulte M, Brecht-Krauss D, Werner M et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999;40: Franzius C, Sciuk J, Brinkschmidt C et al. Evaluation of chemotherapy response in primary bone tumors with F- FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000;25: Nair N, Ali A, Green AA et al. Response of osteosarcoma to chemotherapy. Evaluation with F- FDG-PET scans. Clin Positron Imaging 2000;3: Schwartz DL, Rajendran J, Yueh B et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004;130: Downloaded from by guest on August 14, 20 The Oncologist
Dr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationF NaF PET/CT in the Evaluation of Skeletal Malignancy
F NaF PET/CT in the Evaluation of Skeletal Malignancy Andrei Iagaru, MD September 26, 2013 School of of Medicine Ø Introduction Ø F NaF PET/CT in Primary Bone Cancers Ø F NaF PET/CT in Bone Metastases
More informationEvaluation of Lung Cancer Response: Current Practice and Advances
Evaluation of Lung Cancer Response: Current Practice and Advances Jeremy J. Erasmus I have no financial relationships, arrangements or affiliations and this presentation will not include discussion of
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More informationPET-CT for radiotherapy planning in lung cancer: current recommendations and future directions
PET-CT for radiotherapy planning in lung cancer: current recommendations and future directions Gerry Hanna Centre for Cancer Research and Cell Biology Queen s University of Belfast @gerryhanna Talk Outline
More informationNuclear medicine in oncology. 1. Diagnosis 2. Therapy
Nuclear medicine in oncology 1. Diagnosis 2. Therapy Diagnosis - Conventional methods - Nonspecific radiopharmaceuticals cumulating in tumours - Specific radiopharmaceuticals (receptor- and immunoscintigraphy)
More informationDoes PET/CT Have an Additional Value in Detection of Osteolytic Bone Metastases.
Egyptian J. Nucl. Med., Vol 2, No. 2, Dec. 2009 65 ONCOLOGY, Original Article Does PET/CT Have an Additional Value in Detection of Osteolytic Bone Metastases. R. Riad, M.D.*, M. Awad, M.D. **, E. Eldebawy,
More informationEsophageal Cancer. What is the value of performing PET scan routinely for staging of esophageal cancers
Esophageal Cancer What is the value of performing PET scan routinely for staging of esophageal cancers What is the sensitivity and specificity of PET scan for metastatic lesions When should PET scan be
More informationPET/CT Frequently Asked Questions
PET/CT Frequently Asked Questions General Q: Is FDG PET specific for cancer? A: No, it is a marker of metabolism. In general, any disease that causes increased metabolism can result in increased FDG uptake
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationUtility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationUnusual Osteoblastic Secondary Lesion as Predominant Metastatic Disease Spread in Two Cases of Uterine Leiomyosarcoma
49 Unusual Osteoblastic Secondary Lesion as Predominant Metastatic Disease Spread in Two Cases of Uterine Leiomyosarcoma Loredana Miglietta a Maria Angela Parodi b Luciano Canobbio b Luca Anselmi c a Medical
More informationPOSITRON EMISSION TOMOGRAPHY (PET)
Status Active Medical and Behavioral Health Policy Section: Radiology Policy Number: V-27 Effective Date: 08/27/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY
ANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY Note: These surveillance recommendations are provided as recommendations only. Clinicians should take into account
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationUsing PET/CT in Prostate Cancer
Using PET/CT in Prostate Cancer Legal Disclaimer These materials were prepared in good faith by MITA as a service to the profession and are believed to be reliable based on current scientific literature.
More informationPET Assessment of Tumor Hypoxia
PET Assessment of Tumor Hypoxia Farrokh Dehdashti, M.D. Mallinckrodt Institute of Radiology Washington University St. Louis, Missouri 9/30/10 This work was supported by National Institute of Health R21
More informationPage: 1 of 29. For this policy, PET scanning is discussed for the following 4 applications in oncology:
Emission Tomography Scanning Page: 1 of 29 Last Review Status/Date: June 2015 Description Positron emission tomography (PET) scans are based on the use of positron-emitting radionuclide tracers coupled
More informationRadiological assessment of neoadjuvent chemotherapy for breast cancer
XV th Balkan Congress of Radiology Budapest, Hungary, October 12 15, 2017 Radiological assessment of neoadjuvent chemotherapy for breast cancer V. Bešlagić C l i n i c o f R a d i o l o g y, U n i v e
More informationThe Lessons of GIST PET and PET/CT: A New Paradigm for Imaging
The Lessons of GIST PET and PET/CT: A New Paradigm for Imaging Annick D. Van den Abbeele Dana-Farber Cancer Institute, Boston, Massachusetts, USA Key Words. Positron emission tomography Computed tomography
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
PET Scanning: Oncologic Applications Page 1 of 88 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Positron Emission Tomography (PET) Scanning: Oncologic Applications
More informationThe Use of PET Scanning in Urologic Oncology
The Use of PET Scanning in Urologic Oncology Dr Nicholas C. Buchan Uro-oncology Fellow 1 2 Aims To understand the basic concepts underlying PET scanning. Understand the emerging role of PET Scanning for
More informationMathieu Hatt, Dimitris Visvikis. To cite this version: HAL Id: inserm
Defining radiotherapy target volumes using 18F-fluoro-deoxy-glucose positron emission tomography/computed tomography: still a Pandora s box?: in regard to Devic et al. (Int J Radiat Oncol Biol Phys 2010).
More informationM etastatic disease influences patient management; Whole body PET/CT for initial staging of choroidal melanoma SCIENTIFIC REPORT
1270 SCIENTIFIC REPORT Whole body PET/CT for initial staging of choroidal P T Finger, M Kurli, S Reddy, L B Tena, A C Pavlick... Aim: To investigate the value of whole body positron emission tomography/computed
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationRelationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors
270 ORIGINAL Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors Yoichi Otomi, Hideki Otsuka, Naomi Morita, Kaori Terazawa, Kaori Furutani, Masafumi Harada,
More informationPET/CT in oncology. Positron emission tomography
Clinical Medicine 2012, Vol 12, No 4: 368 72 PET/CT in oncology Fahim-Ul-Hassan, SpR Nuclear Medicine, Guy s Hospital, London; Gary J Cook, professor of Clinical PET, KCL Division of Imaging Sciences &
More informationMolecular Imaging in the Development of Cancer Therapeutics. Johannes Czernin
Molecular Imaging in the Development of Cancer Therapeutics Johannes Czernin Ahmanson Biological Imaging Division University of California Los Angeles Cancer Statistics Cancer Type 5-year Survival Rate
More informationPositron Emission Tomography in Lung Cancer
May 19, 2003 Positron Emission Tomography in Lung Cancer Andrew Wang, HMS III Patient DD 53 y/o gentleman presented with worsening dyspnea on exertion for the past two months 30 pack-year smoking Hx and
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationReference No: Author(s) NICaN Drugs and Therapeutics Committee. Approval date: 12/05/16. January Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Gastro- Intestinal Stromal Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More information1 Introduction. 2 Materials and methods. LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1
Nuclear Science and Techniques 20 (2009) 354 358 18 F-FDG PET/CT in diagnosis of skeletal metastases LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1 1 Department of Nuclear Medicine,
More informationAn Introduction to PET Imaging in Oncology
January 2002 An Introduction to PET Imaging in Oncology Janet McLaren, Harvard Medical School Year III Basics of PET Principle of Physiologic Imaging: Allows in vivo visualization of structures by their
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationCitation for published version (APA): Francken, A. B. (2007). Primary and metastatic melanoma: aspects of follow-up and staging s.n.
University of Groningen Primary and metastatic melanoma Francken, Anne Brecht IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationPrinciples of nuclear metabolic imaging. Prof. Dr. Alex Maes AZ Groeninge Kortrijk and KULeuven Belgium
Principles of nuclear metabolic imaging Prof. Dr. Alex Maes AZ Groeninge Kortrijk and KULeuven Belgium I. Molecular imaging probes A. Introduction - Chemical disturbances will precede anatomical abnormalities
More informationPositron emission tomography/computer tomography in the evaluation of head and neck cancer treatment
Positron emission tomography/computer tomography in the evaluation of head and neck cancer treatment Severina Šedienė 1, Ilona Kulakienė 1, Viktoras Rudžianskas 2 1 Lithuanian University of Health Sciences,
More informationBone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When PET Scans Findings Are Equivocal: A Case Report
Bone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When Scans Findings Are Equivocal: A Case Report Yuk-Wah Tsang 1, Jyh-Gang Leu 2, Yen-Kung Chen 3, Kwan-Hwa Chi 1,4
More informationUnfolding the role of PET FDG scan in the management of thyroid incidentaloma in cancer patients
DOI 10.1007/s00405-014-3120-5 Head and Neck Unfolding the role of PET FDG scan in the management of thyroid incidentaloma in cancer patients Haim Gavriel Adrian Tang Ephraim Eviatar Sor Way Chan Received:
More informationEffective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
More informationRadiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer
Radiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer Poster No.: C-0654 Congress: ECR 2011 Type: Scientific Paper Authors:
More informationThe Role of PET / CT in Lung Cancer Staging
July 2004 The Role of PET / CT in Lung Cancer Staging Vlad Vinarsky, Harvard Medical School Year IV Patient AM HPI: 81 yo F p/w hemoptysis x 1 month LLL lesion on CXR, not responsive to Abx 35 pack-year
More informationColorectal Cancer and FDG PET/CT
Hybrid imaging in colorectal & esophageal cancer Emmanuel Deshayes IAEA WorkShop, November 2017 Colorectal Cancer and FDG PET/CT 1 Clinical background Cancer of the colon and rectum is one of the most
More informationMolecular Imaging and Cancer
Molecular Imaging and Cancer Cancer causes one in every four deaths in the United States, second only to heart disease. According to the U.S. Department of Health and Human Services, more than 512,000
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
PET Scanning: Oncologic Applications Page 1 of 42 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Positron Emission Tomography (PET) Scanning: Oncologic
More informationUtility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC)
Utility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC) Poster No.: C-1360 Congress: ECR 2015 Type: Scientific Exhibit Authors:
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationThe Proper Use of PET/CT in Tumoring Imaging
The Proper Use of PET/CT in Tumoring Imaging Mijin Yun, M.D. Jong Doo Lee, M.D. Department of Radiology / Division of Nuclear Medicine Yonsei University College of Medicine, Severance Hospital E mail :
More informationZurich Open Repository and Archive
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2008 The additional value of CT images interpretation in the differential diagnosis
More informationClinical indications for positron emission tomography
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
More informationOncologic Applications of PET Scanning
6.01.26 Oncologic Applications of PET Scanning Section 6.0 Radiology Subsection Effective Date February 15, 2015 Original Policy Date January 26, 2009 Next Review Date December 2015 Description Positron
More informationOriginal Policy Date
MP 6.01.17 Oncologic Applications of PET Scanning Medical Policy Section Radiology Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature/12:2013 Return to Medical
More informationCT PET SCANNING for GIT Malignancies A clinician s perspective
CT PET SCANNING for GIT Malignancies A clinician s perspective Damon Bizos Head, Surgical Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital Case presentation 54 year old with recent onset
More informationAssessment of renal cell carcinoma by two PET tracer : dual-time-point C-11 methionine and F-18 fluorodeoxyglucose
Assessment of renal cell carcinoma by two PET tracer : dual-time-point C-11 methionine and F-18 fluorodeoxyglucose Poster No.: C-0805 Congress: ECR 2015 Type: Scientific Exhibit Authors: S. Ito, K. Kato,
More informationBone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors
Bone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors Lars Stegger, Benjamin Noto Department of Nuclear Medicine University Hospital Münster, Germany Content From PET to
More informationAppendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer
Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer Locoregional (N stage) disease was redefined in the seventh edition of the AJCC Cancer Staging Manual as any periesophageal lymph
More informationTHE ROLE OF CONTEMPORARY IMAGING AND HYBRID METHODS IN THE DIAGNOSIS OF CUTANEOUS MALIGNANT MELANOMA(CMM) AND MERKEL CELL CARCINOMA (MCC)
THE ROLE OF CONTEMPORARY IMAGING AND HYBRID METHODS IN THE DIAGNOSIS OF CUTANEOUS MALIGNANT MELANOMA(CMM) AND MERKEL CELL CARCINOMA (MCC) I.Kostadinova, Sofia, Bulgaria CMM some clinical facts The incidence
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationPositron emission tomography Medicare Services Advisory Committee
Positron emission tomography Medicare Services Advisory Committee Authors' objectives To assess the effectiveness of positron emission tomography (PET), the report addressed the following (truncated) six
More informationQuantitative Nuclear Medicine Imaging in Oncology. Susan E. Sharp, MD
Quantitative Nuclear Medicine Imaging in Oncology Susan E. Sharp, MD Disclosures None Objectives Describe scoring systems used in oncologic nuclear medicine imaging Deauville scoring in lymphoma Curie
More informationWHAT DOES PET IMAGING ADD TO CONVENTIONAL STAGING OF HEAD AND NECK CANCER PATIENTS?
doi:10.1016/j.ijrobp.2006.12.044 Int. J. Radiation Oncology Biol. Phys., Vol. 68, No. 2, pp. 383 387, 2007 Copyright 2007 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/07/$ see front
More informationExecutive Summary. Positron emission tomography (PET and PET/CT) in malignant lymphoma 1. IQWiG Reports Commission No. D06-01A
IQWiG Reports Commission No. D06-01A Positron emission tomography (PET and PET/CT) in malignant lymphoma 1 Executive Summary 1 Translation of the executive summary of the final report Positronenemissionstomographie
More information8/10/2016. PET/CT for Tumor Response. Staging and restaging Early treatment response evaluation Guiding biopsy
PET/CT for Tumor Response Evaluation August 4, 2016 Wei Lu, PhD Department of Medical Physics www.mskcc.org Department of Radiation Oncology www.umaryland.edu FDG PET/CT for Cancer Imaging Staging and
More informationHemorrhoids: A Possible Cause of High FDG Uptake in the Rectum
Hemorrhoids: A Possible Cause of High FDG Uptake in the Rectum Yu-Yu Lu, Wan-Yu Lin Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung, Taiwan A 52-year-old man underwent 18 F-FDG
More informationPET/CT in breast cancer staging
PET/CT in breast cancer staging Anni Morsing Consultant, PhD, DMSc Rigshospitalet 1 18F- FDG PET/CT for breastcancer staging Where is the clinical impact? To which women should 18F- FDG PET/CT be offered?
More informationPitfalls in Oncologic Diagnosis with PET CT. Nononcologic Hypermetabolic Findings
Pitfalls in Oncologic Diagnosis with PET CT. Nononcologic Hypermetabolic Findings Poster No.: C-1359 Congress: ECR 2012 Type: Educational Exhibit Authors: J. Rossi 1, C. A. Mariluis 1, E. Delgado 1, R.
More informationPET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany
PET-MRI in malignant bone tumours Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany Content From PET to PET/MRI General considerations Bone metastases Primary bone tumours
More informationUK Musculoskeletal Oncology: Something for All Ages. Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky
UK Musculoskeletal Oncology: Something for All Ages Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky Pediatric-Type Sarcomas of Bone and Soft Tissue The incidence of sarcoma continues
More informationPET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET
Positron Emission Tomography (PET) When calling Anthem (1-800-533-1120) or using the Point of Care authorization system for a Health Service Review, the following clinical information may be needed to
More informationResponse Assessment in Clinical Trials: Implications for Sarcoma Clinical Trial Design
Response Assessment in Clinical Trials: Implications for Sarcoma Clinical Trial Design C. Carl Jaffe Diagnostic Imaging Branch, Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National
More informationLugano classification: Role of PET-CT in lymphoma follow-up
CAR Educational Exhibit: ID 084 Lugano classification: Role of PET-CT in lymphoma follow-up Charles Nhan 4 Kevin Lian MD Charlotte J. Yong-Hing MD FRCPC Pete Tonseth 3 MD FRCPC Department of Diagnostic
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationPET tracer development a tale of mice and men
Cancer Imaging (2006) 6, S102 S106 DOI: 10.1102/1470-7330.2006.9098 CI MINI SYMPOSIUM: PET THE FUTURE Tuesday 17 October 2006, 14:00 15:30 PET tracer a tale of mice and men Rodney J Hicks, Donna Dorow
More informationPET/CT in Breast Cancer
PET/CT in Breast Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria Overview Introduction Locorregional
More informationPET in Prostate Cancer
PET in Prostate Cancer Tom R. Miller, M.D., Ph.D. Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, Missouri, USA Prostate Imaging Bone Scintigraphy primarily for
More informationIAEA RTC. PET/CT and Planning of Radiation Therapy 20/08/2014. Sarajevo (Bosnia & Hercegovina) Tuesday, June :40-12:20 a.
IAEA RTC PET/CT and Planning of Radiation Therapy Sarajevo (Bosnia & Hercegovina) Tuesday, June 17 2014 11:40-12:20 a.m María José García Velloso Servicio de Medicina Nuclear Clínica Universidad de Navarra
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationExtra-articular Knee Lesion with High Fluorodeoxyglucose-Uptake on Positron Emission Tomography
170 Extra-articular Knee Lesion with High Fluorodeoxyglucose-Uptake on Positron Emission Tomography Justin C. Paul, M.D., Ph.D., Aasis Unnanuntana, M.D., Stanley J. Goldsmith, M.D., and Joseph M. Lane,
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationPET/MR:Techniques, Indications and Applications
PET/MR:Techniques, Indications and Applications Franz Wolfgang Hirsch Professor and Head of the Department of Pediatric Radiology University Hospital Leipzig / Germany Children s Hospital University Leipzig
More informationGiant gastrointestinal stromal tumor of the jejunum resected after treatment with imatinib
Int Canc Conf J (2012) 1:41 46 DOI 10.1007/s13691-011-0007-9 CASE REPORT Giant gastrointestinal stromal tumor of the jejunum resected after treatment with imatinib Kaori Shigemitsu Takako Yamada Shinichiro
More information2004 SNM Mid-Winter Educational Symposium
1 2 20 Numeric values 15 10 5 0 SUV corr hs 18FDG Slope corr hs SUV corr hs Slope corr hs 11C-methionin 3 11C-methionine Grading and delineation of brain tumors Differentiation of malignant from benign
More informationAnnals of Oncology Advance Access published February 2, 2011
Advance Access published February 2, 2011 original article doi:10.1093/annonc/mdq696 Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal
More informationMultidisciplinary management of retroperitoneal sarcomas
Multidisciplinary management of retroperitoneal sarcomas Eric K. Nakakura, MD UCSF Department of Surgery UCSF Comprehensive Cancer Center San Francisco, CA 7 th Annual Clinical Cancer Update North Lake
More informationVIII. 9. FDG-PET for Diagnosis of an Advanced Jejunal Adenocarcinoma with Distant Metastases, Compared with Gallium Scintigraphy
CYRIC Annual Report 2003 VIII. 9. FDG-PET for Diagnosis of an Advanced Jejunal Adenocarcinoma with Distant Metastases, Compared with Gallium Scintigraphy Yamaura G., Yoshioka T., Yamaguchi K. *, Fukuda
More informationClinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationPET Imaging in Langerhans Cell Histiocytosis
PET Imaging in Langerhans Cell Histiocytosis Christiane Franzius Bremen, Germany Histiocytosis Histiocytosis Idiopathic proliferation of histiocytes Two types of histiocytes macrophages: antigen processing
More informationSELF-ASSESSMENT MODULE REFERENCE SPR 2018 Oncologic Imaging Course Adrenal Tumors November 10, :00 12:10 p.m.
SELF-ASSESSMENT MODULE REFERENCE SPR 2018 Oncologic Imaging Course Adrenal Tumors November 10, 2018 10:00 12:10 p.m. Staging Susan E. Sharp, MD 1. In the International Neuroblastoma Risk Group Staging
More informationNuclear Sciences and Medicine
Nuclear Sciences and Medicine Rethy Chhem, MD, PhD (Edu), PhD (His), FRCPC Division of Human Health Guest Professor, Medical University of Vienna International Atomic Energy Agency Medical Imaging X-rays
More informationFDG-PET/CT for cancer management
195 REVIEW FDG-PET/CT for cancer management Hideki Otsuka, Naomi Morita, Kyo Yamashita, and Hiromu Nishitani Department of Radiology, Institute of Health Biosciences, The University of Tokushima, Graduate
More informationColorectal cancer is the second most common cancer,
PET Changes and Improves Prognostic Stratification in Patients with Recurrent Colorectal Cancer: Results of a Multicenter Prospective Study Andrew M. Scott 1,2, Dishan H. Gunawardana 1, Ben Kelley 3, John
More informationLocal Therapy for Ewing Sarcoma: Current Concepts and Opportunities for Improvement
Local Therapy for Ewing Sarcoma: Current Concepts and Opportunities for Improvement Safia K. Ahmed, MD Department of Radiation Oncology Washington University August 25, 2017 2017 MFMER slide-1 Outline
More informationStaging Colorectal Cancer
Staging Colorectal Cancer CT is recommended as the initial staging scan for colorectal cancer to assess local extent of the disease and to look for metastases to the liver and/or lung Further imaging for
More informationTriage of Limited Versus Extensive Disease on 18 F-FDG PET/CT Scan in Small Cell lung Cancer
Triage of Limited Versus Extensive Disease on F-FDG PET/CT Scan in Small Cell lung Cancer Riaz Saima 1*, Bashir Humayun 1, Niazi Imran Khalid 2 1 Department of Nuclear Medicine, Shaukat Khanum Memorial
More informationL impatto dell imaging sulla definizione della strategia terapeutica
GISCoR L impatto dell imaging sulla definizione della strategia terapeutica M. Galeandro U.C. Radioterapia Oncologica ASMN-IRCCS Reggio Emilia 14 Novembre 2014 Rectal Cancer TNM AJCC-7 th edition 2010
More information